
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is poised for success in the rapidly advancing healthcare industry as a multi-cancer early detection company. With the potential to detect all types of cancers at all stages through their pioneering blood test technology, GRAIL is well positioned to revolutionize cancer diagnosis and save lives. The company's strong partnerships, impressive growth in test volumes, and focus on addressing price elasticity all contribute to a positive outlook for GRAIL's future profitability.
Bears say
GRAIL is a healthcare company that has developed a multi-cancer early detection blood test, but despite a 2% revenue increase and projected screening revenue growth, it has continued to offer discounts and its F'26 model is expected to be lower than originally forecasted. As a result, its PT remains at $69, reflecting a more modest outlook due to a shorter discount period.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares